Canadian Licensed Producers can export cannabis to the Netherlands by obtaining a Health Canada export permit and working with a Dutch licensed importer who holds an Office for Medicinal Cannabis (OMC) import authorisation. This guide covers the full regulatory pathway: the Dutch approval framework, Health Canada permit requirements, what buyers evaluate, and how to structure your market entry.
Few export markets remain as commercially significant and as poorly mapped for Canadian LPs as the Netherlands. Two regulatory bodies control the Dutch medical cannabis supply chain. The Office for Medicinal Cannabis (OMC), a division of the Ministry of Health, Welfare and Sport (VWS), approves imported cannabis products and manages the national pharmacy supply programme. The Medicines Evaluation Board (MEB) governs product licensing for specific formulations. Understanding how both layers interact with Health Canada's export permit process is what separates LPs that close supply agreements from those that stall at pre-qualification.
How the Netherlands regulates medical cannabis imports
Europe doesn't have many medical cannabis programmes as tightly controlled as the Netherlands'. The OMC approves imported products and has historically managed domestic supply through Bedrocan, its appointed producer.
That dual role matters for you as a Canadian LP. The Netherlands isn't a fully open import market in the way Germany became following its 2024 liberalisation. Imported cannabis must either match an existing OMC product monograph or pass through a specific import dossier review by the OMC and MEB. That review adds time and documentation that you'll want to plan for before approaching Dutch buyers.
Import authorisation pathway
A Dutch pharmacy, hospital, or licensed importer wishing to source from a Canadian LP must file for an import authorisation under the Opium Act (Opiumwet). That authorisation requires:
- A named product with confirmed cannabinoid specifications (THC, CBD, CBN within defined tolerances)
- A Certificate of Analysis from a laboratory accredited to ISO/IEC 17025
- Evidence of GMP compliance (Health Canada GMP is accepted in most OMC file reviews, though EU-GMP documentation may be requested for pharmacy-grade channels)
- A phytosanitary certificate from the Canadian Food Inspection Agency (CFIA)
- A valid Health Canada export permit under the Cannabis Act
One point that regularly catches LPs off guard: your Dutch partner holds the import authorisation, not your company. You need a named Dutch partner confirmed before a Health Canada export permit application makes commercial sense.
Health Canada export permit requirements for the Netherlands
Health Canada processes cannabis export permit applications under Part 14 of the Cannabis Regulations. The Netherlands is a permissible destination under the Single Convention on Narcotic Drugs (1961), to which both countries are signatories. The legal framework exists. Execution is where delays happen.
For a full walkthrough of the permit process, see our export permit guide.
What Health Canada requires for a Netherlands export permit
- Completed application (EC-0127 or current active form at time of submission)
- Import permit or authorisation from the Dutch competent authority (OMC or VWS, depending on the channel)
- Product description: dried flower, batch size, THC/CBD content
- LP licence in good standing with export endorsement visible
- Proposed shipment method and port of exit
Health Canada's processing window for complete applications is typically 10 to 25 business days. Missing the Dutch import authorisation number is the most common cause of hold-ups. Confirm your Dutch partner has received their authorisation before you trigger the Canadian permit process.
Permit scope
Each permit covers a single shipment: one batch, one quantity, one destination. For ongoing supply, you and your Dutch partner will typically run a framework agreement and apply per confirmed order. There's no blanket annual export licence for flower shipments to the Netherlands.
What Dutch buyers evaluate in a Canadian LP
Dutch buyers are demanding. Pharmacy networks and licensed distributors hold Canadian LPs to a tighter specification checklist than most other export markets. The OMC's historical product standards, built around Bedrocan's domestic programme, shape what buyers expect from imported flower.
Batch-to-batch consistency
Dutch pharmacies dispense cannabis to patients under medical supervision. Variation in THC percentage, moisture content, or microbial load across batches creates clinical and compliance risk for the dispensing pharmacist. LPs without documented batch consistency data (ideally across three to five consecutive harvests) typically face extended pre-qualification reviews.
COA panel requirements
Dutch buyers expect the following panels at minimum:
- Potency: THC, CBD, CBN, THCA
- Terpene profile via GC-MS or equivalent
- Residual solvents (if any processing step was involved)
- Pesticide and heavy metal screening against EU Pharmacopoeia thresholds
- Microbial count: total aerobic count, moulds and yeasts, E. coli, Salmonella
- Water activity and moisture content
Missing those panels? Add them before you reach out to Dutch partners. That gap surfaces in technical due diligence and can delay onboarding by months.
GMP documentation
Health Canada GMP is generally accepted. But LPs with EU-GMP certification enter Dutch conversations with a shorter qualification timeline. The OMC has approved Health Canada GMP-certified facilities in past reviews, though the pathway involves more documentation than an EU-GMP supplier provides. AlphaLeaf's Montreal indoor facility operates under Health Canada GMP standards with full batch traceability and ISO/IEC 17025-accredited testing, providing a solid documentation foundation for OMC file review.
Building a Netherlands market entry approach
The Dutch market rewards LPs who lead with structured partner identification. The distribution channel is narrower than Germany's: a small number of licensed importers service the national pharmacy network. Working with the right intermediary matters more than how many contacts you reach.
Step 1: Identify and qualify a licensed Dutch importer
The OMC maintains a register of authorised cannabis importers. Confirm any prospective partner appears on that register before sharing product dossiers or entering NDA discussions. Importers without active authorisations can't file the Dutch side of the permit application.
Step 2: Prepare a technical product dossier
Before formal outreach, assemble:
- At least three consecutive batch COAs covering all panels above
- Facility overview: indoor square footage, cultivation method, quality management system
- Current Health Canada licence copy with export authorisation visible
- ISO/IEC 17025 accreditation certificate for your testing laboratory
- Stability data, if available
Step 3: Align on product specification
Dutch buyers typically specify the cultivar and cannabinoid range they want listed in pharmacy systems. If you have multiple genetics, you have flexibility. Single-cultivar LPs should confirm their specification matches a product type the Dutch importer can actually place with pharmacies before advancing to sampling.
Step 4: Run a product sampling round
Dutch pharmacy buyers and clinical reviewers typically request physical samples before filing for import authorisation. Under the Cannabis Act, small-quantity sample shipments require a separate Health Canada sample export authorisation. Plan for four to eight weeks at this stage depending on Dutch review timelines.
Step 5: File both permits concurrently
Once your Dutch partner is ready to file, both the Dutch import authorisation and your Health Canada export permit can run in parallel. Coordination between your regulatory team and the Dutch importer's compliance function at this stage is what determines whether the first shipment lands on schedule or slips by a quarter.
Frequently Asked Questions
Does the Netherlands accept Health Canada GMP-certified facilities for cannabis imports?
The OMC has accepted Health Canada GMP certification in past import authorisation reviews. The process involves more documentation than EU-GMP-certified suppliers provide, but it's not a disqualifying barrier. LPs with EU-GMP certification or a formal equivalency letter from a recognised EU body typically move through Dutch pre-qualification faster.
How long does a Dutch import authorisation take to process?
First-time import authorisations for a new product have taken between six and sixteen weeks. Build this into your export timeline and don't begin the Health Canada permit application until the Dutch authorisation number is confirmed.
Can a Canadian LP sell directly to Dutch pharmacies?
No. Dutch pharmacies source cannabis through licensed importers holding Opium Act import authorisations. You contract with the licensed importer, who then supplies the pharmacy network. Direct pharmacy relationships work well for product education and clinical communication but they don't replace the importer in the regulatory and commercial chain.
What is the practical minimum batch size for a Netherlands export?
There's no regulatory minimum. The economics of export permit preparation, phytosanitary certification, and international freight make shipments below approximately 20 kg difficult to justify as standalone transactions. Most first commercial shipments range from 20 to 100 kg, with ongoing quantities set out in the framework contract.
Do Dutch buyers require terpene profiles on the COA?
Yes, in practice. Dutch pharmacy buyers expect terpene profiles as part of standard product documentation, even where the OMC's formal requirements don't explicitly mandate them. Submitting a COA without terpene data slows pre-qualification. Make sure your testing laboratory delivers GC-MS terpene analysis on every batch.
